Skip to main content

CORRECTION article

Front. Pharmacol., 20 October 2021
Sec. Pharmacology of Anti-Cancer Drugs
Volume 12 - 2021 | https://doi.org/10.3389/fphar.2021.785732

Corrigendum: Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy

This article is a correction to:

  1. Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy

    1. Read original article
Yihui Zhou&#x;Yihui Zhou1†Xiaomeng Gao&#x;Xiaomeng Gao1†Meng YuanMeng Yuan2Bo Yang,Bo Yang1,2Qiaojun He,, Qiaojun He1,2,3*Ji Cao,, Ji Cao1,2,3*
  • 1Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
  • 2The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, China
  • 3Cancer Center of Zhejiang University, Hangzhou, China

A Corrigendum on
Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy

by Zhou, Y., Gao, X., Yuan, M., Yang, B., He, Q., and Cao, J. (2021). Front. Pharmacol. 12:748852. doi: 10.3389/fphar.2021.748852

In the published article, there was an error regarding the Affiliation for Meng Yuan. Instead of “Cancer Center of Zhejiang University, Hangzhou, China,” the correct affiliation is “The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, China.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: MYC, cancer therapy, interaction protein, transcriptional regulation, post-translational modification, inhibitors

Citation: Zhou Y, Gao X, Yuan M, Yang B, He Q and Cao J (2021) Corrigendum: Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy. Front. Pharmacol. 12:785732. doi: 10.3389/fphar.2021.785732

Received: 29 September 2021; Accepted: 30 September 2021;
Published: 20 October 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Zhou, Gao, Yuan, Yang, He and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Qiaojun He, qiaojunhe@zju.edu.cn; Ji Cao, caoji88@zju.edu.cn

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.